Bright Minds Biosciences Inc.
NASDAQ:DRUGBiotechnology
+$0.62 today
- Market cap
- $204.78M
- Beta
- -0.11
- P/E (TTM)
- -29.8
- EPS (TTM)
- -$2.87
Volume 0.14M
Average 0.27M
DRUG Effect of Forex Changes
Change in reported cash caused by exchange-rate movements on foreign-currency balances.
Bright Minds Biosciences Inc.NASDAQ: DRUG
Effect of Forex Changes · Q2 FY2026 · quarter ended Mar 2026
Effect of forex changes growth accelerates
Q2 FY2026 effect of forex changes of CA$4.12M (cash outflow) rose 24334.6% year over year, ahead of the -510.5% change in trailing-twelve-month effect of forex changes. Sequentially, it rose 186.8% from the prior quarter. Over 3 fiscal years it compounded at +6.5% a year.
Context
- Effect of forex changes increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +24334.6% holds above the trailing-twelve-month pace of -510.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Effect of Forex Changes history
CAD · from the cash flow
- Latest · FY2025
- 312.63K CAD
- Year-over-year change
- +2567.4%
- 4-year CAGR
- +8.7%
| Period | Period end | Effect of Forex Changes | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 312.63K | +2567.4% |
| FY2024 | 2024-09-30 | 11.72K | +125.8% |
| FY2023 | 2023-09-30 | (45.35K) | -117.5% |
| FY2022 | 2022-09-30 | 258.82K | +15.7% |
| FY2021 | 2021-09-30 | 223.79K | — |
Effect of Forex Changes vs competitors
How DRUG compares with its peers on the latest reported figures
No competitor Effect of Forex Changes figures are available to compare.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (8.65M) | (14.96M) | (7.37M) | (2.8M) | (12.23M) |
| Depreciation & Amortization | 0 | 6.04K | 72.45K | 73.36K | 76.87K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 880.62K | 875.06K | 1.15M | 839.77K | 3.18M |
| Change in Working Capital | 306.08K | 724.13K | (941.72K) | 39.81K | 554.99K |
| Accounts Receivables | (110.15K) | (45.63K) | 118.8K | (13.24K) | (362.85K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 416.23K | 769.77K | (1.06M) | 53.06K | 917.84K |
| Other Non-Cash Items | 144.76K | (227.4K) | 65.1K | (1.18K) | (276.84K) |
| Operating Cash Flow | (7.32M) | (13.59M) | (7.02M) | (1.85M) | (8.69M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | 0 | 0 |
| Debt Repayment | 0 | (7.16K) | (86.11K) | (89.73K) | (100.15K) |
| Common Stock Issued | 27.74M | 4.03M | 1.22M | 900.3K | 86.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.69M) | 1.17M | 1.06M | 0 | (360.14K) |
| Financing Cash Flow | 26.06M | 5.2M | 2.19M | 810.57K | 85.57M |
| Effect of Forex Changes | 223.79K | 258.82K | (45.35K) | 11.72K | 312.63K |
| Net Change in Cash | 18.96M | (8.13M) | (4.88M) | (1.03M) | 77.19M |
| Free Cash Flow | (7.32M) | (13.59M) | (7.02M) | (1.85M) | (8.69M) |
Bright Minds Biosciences Inc.
NASDAQ:DRUG
Intrinsic Alpha fair value
Locked
Current Price
$20.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.